News

Under the deal, Pfizer acquired a portion of Baxter’s facility in Orth, Austria, which manufactures meningitis vaccine, NeisVac-C as well as the encephalitis vaccine, FSME-IMMUN/TicoVac. NeisVac-C is a

Around 1,500 patients in 15 countries will be enrolled in the trial which is designed to evaluate the safety and efficacy of AZD3293/LY3314814 compared with placebo in the

The new facility is aimed to boost the company’s local manufacturing capability to handle increasing demand in China for its peripheral neuropathy treatment Methycobal injection in expectation of

As part of its plans, the company has decided to focus its Osaka plant to become a specialty manufacturing site for prostate and breast cancer drug Leuplin/Lupron (leuprorelin).

Featuring contributions from leading analysts, professional representatives and patient groups, the event combined theexperience and views of Merck Consumer Health’s senior management team with external perspectives on the

Alimera has also agreed to issue an additional 124.378 shares of preferred stock as a subscription premium. The preferred stock will be convertible into an aggregate of 8,416,251

The licence will enable other companies and organisations to re-formulate and manufacture specially designed LPV/r and r paediatric treatments for distribution in low- and middle-income countries where 99%

The sBLA was based on an international, multi-center, double-blind, randomized, placebo-controlled Phase III trial which included around 250 adult patients with upper limb spasticity. The trial, which was

As part of the deal, UCB will manufacture and supply the product for commercialisation and Daiichi will manage the distribution and book sales. The deal, which is subject